BR112018075420A2 - melhoramento da imunogenicidade de petídeo l2 - Google Patents
melhoramento da imunogenicidade de petídeo l2Info
- Publication number
- BR112018075420A2 BR112018075420A2 BR112018075420-0A BR112018075420A BR112018075420A2 BR 112018075420 A2 BR112018075420 A2 BR 112018075420A2 BR 112018075420 A BR112018075420 A BR 112018075420A BR 112018075420 A2 BR112018075420 A2 BR 112018075420A2
- Authority
- BR
- Brazil
- Prior art keywords
- relates
- present
- immunogenic polypeptide
- hpv
- terminal
- Prior art date
Links
- 230000005847 immunogenicity Effects 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 7
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 7
- 229920001184 polypeptide Polymers 0.000 abstract 5
- 230000002163 immunogen Effects 0.000 abstract 4
- 241000701806 Human papillomavirus Species 0.000 abstract 1
- 102400000108 N-terminal peptide Human genes 0.000 abstract 1
- 101800000597 N-terminal peptide Proteins 0.000 abstract 1
- 208000009608 Papillomavirus Infections Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
- A61K2039/645—Dendrimers; Multiple antigen peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
a presente invenção se refere a um polipeptídeo imunogênico compreendendo uma multiplicidade de peptídeos l2 n-terminais do papilomavirus humano (hpv) correspondendo aos aminoácidos 20 a 50 do polipeptídeo l2 de hpv16, em que os referidos peptídeos n-terminais l2 de hpv são peptídeos l2- n-terminal de pelo menos dois genótipos diferentes de hpv. a presente invenção também se refere ao referido polipeptídeo imunogênico para utilização em medicina e para utilização na vacinação contra a infecção por hpv. além disso, a presente invenção se refere a um polinucleotídeo codificando o polipeptídeo imunogênico e a uma célula hospedeira compreendendo o mesmo. além disso, a presente invenção refere-se a kits, métodos e usos relacionados ao polipeptídeo imunogênico da invenção.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16173313.4 | 2016-06-07 | ||
| EP16173313 | 2016-06-07 | ||
| PCT/EP2017/063833 WO2017211886A1 (en) | 2016-06-07 | 2017-06-07 | Improvement of hpv l2 peptide immunogenicity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018075420A2 true BR112018075420A2 (pt) | 2019-03-12 |
Family
ID=56148123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018075420-0A BR112018075420A2 (pt) | 2016-06-07 | 2017-06-07 | melhoramento da imunogenicidade de petídeo l2 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10736954B2 (pt) |
| EP (1) | EP3463444A1 (pt) |
| JP (1) | JP6974358B2 (pt) |
| CN (1) | CN109310749B (pt) |
| AR (1) | AR108781A1 (pt) |
| AU (1) | AU2017276698B2 (pt) |
| BR (1) | BR112018075420A2 (pt) |
| CA (1) | CA3025855A1 (pt) |
| RU (1) | RU2743016C2 (pt) |
| WO (1) | WO2017211886A1 (pt) |
| ZA (1) | ZA201808246B (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3078536A1 (fr) * | 2018-03-05 | 2019-09-06 | Peptinov Sas | Composition vaccinale anti-pd-1 |
| FR3078535B1 (fr) * | 2018-03-05 | 2024-02-09 | Peptinov Sas | Composition vaccinale anti-pd-l1 |
| EP3773708A2 (en) | 2018-04-03 | 2021-02-17 | Sanofi | Antigenic epstein barr virus polypeptides |
| CN112512564A (zh) * | 2018-04-03 | 2021-03-16 | 赛诺菲 | 铁蛋白蛋白 |
| CN112423783A (zh) * | 2018-05-30 | 2021-02-26 | 德国癌症研究中心 | 组合的预防性和治疗性疫苗 |
| SG11202103851PA (en) | 2018-10-18 | 2021-05-28 | Deutsches Krebsforsch | Dry pharmaceutical composition for inhalation |
| BR102019025802A2 (pt) | 2019-12-05 | 2022-01-18 | Instituto Butantan | Processo de produção de uma composição imunológica de dna profilática e terapêutica contra hpv e cânceres associados ao vírus, proteína híbrida, vetor de expressão, composição imunológica e seus usos |
| KR102264535B1 (ko) * | 2020-06-01 | 2021-06-14 | (주)인테라 | 엔캡슐린 기반 백신 생산을 위한 재조합 발현 벡터 및 이의 제조방법 |
| US20240084310A1 (en) * | 2020-06-01 | 2024-03-14 | Inthera Inc. | Recombinant expression vector for production of encapsulin-based vaccine and method for manufacturing the same |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0105606D0 (en) | 2001-03-07 | 2001-04-25 | Cantab Pharmaceuticals Res Ltd | Immunogens and vaccines and their preparation and use |
| EP1576967B1 (en) * | 2004-03-18 | 2007-09-12 | Institut Pasteur | Recombinant protein, carrying human papillomavirus epitopes inserted in an adenylate cyclase protein or fragment thereof, therapeutic uses thereof |
| US20100272753A1 (en) | 2006-10-26 | 2010-10-28 | The Johns Hopkins University | Recombinant Adenovirus Vaccines |
| MX2010004850A (es) * | 2007-11-02 | 2010-12-07 | Univ Johns Hopkins | Composiciones de peptidos de hpv de tipos multiples y metodos para tratamiento o prevencion de infeccion de virus de papiloma humano. |
| EP2199301A1 (en) * | 2008-12-19 | 2010-06-23 | DKFZ Deutsches Krebsforschungszentrum | Immunogenic polypeptides comprising a scaffold polypeptide and a L2 polypeptide or fragment thereof |
| EP2576814A1 (en) | 2010-06-02 | 2013-04-10 | Deutsches Krebsforschungszentrum | High-throughput method for determining the presence of papillomavirus-neutralizing antibodies in a sample |
-
2017
- 2017-06-07 JP JP2018563734A patent/JP6974358B2/ja active Active
- 2017-06-07 AR ARP170101558A patent/AR108781A1/es unknown
- 2017-06-07 RU RU2018142386A patent/RU2743016C2/ru active
- 2017-06-07 EP EP17729447.7A patent/EP3463444A1/en active Pending
- 2017-06-07 AU AU2017276698A patent/AU2017276698B2/en active Active
- 2017-06-07 US US16/308,358 patent/US10736954B2/en active Active
- 2017-06-07 CA CA3025855A patent/CA3025855A1/en active Pending
- 2017-06-07 CN CN201780035734.5A patent/CN109310749B/zh active Active
- 2017-06-07 BR BR112018075420-0A patent/BR112018075420A2/pt unknown
- 2017-06-07 WO PCT/EP2017/063833 patent/WO2017211886A1/en active Search and Examination
-
2018
- 2018-12-06 ZA ZA2018/08246A patent/ZA201808246B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019525735A (ja) | 2019-09-12 |
| US10736954B2 (en) | 2020-08-11 |
| JP6974358B2 (ja) | 2021-12-01 |
| AR108781A1 (es) | 2018-09-26 |
| RU2743016C2 (ru) | 2021-02-12 |
| AU2017276698A1 (en) | 2018-12-20 |
| AU2017276698B2 (en) | 2021-02-18 |
| CN109310749A (zh) | 2019-02-05 |
| US20190125856A1 (en) | 2019-05-02 |
| CN109310749B (zh) | 2022-09-23 |
| CA3025855A1 (en) | 2017-12-14 |
| RU2018142386A3 (pt) | 2020-07-09 |
| EP3463444A1 (en) | 2019-04-10 |
| WO2017211886A1 (en) | 2017-12-14 |
| ZA201808246B (en) | 2022-10-26 |
| RU2018142386A (ru) | 2020-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018075420A2 (pt) | melhoramento da imunogenicidade de petídeo l2 | |
| MX2020006117A (es) | Integracion dirigida de acidos nucleicos. | |
| CO2018001623A2 (es) | Vacunas terapéuticas contra el hpv18 y/o hpv16 | |
| BR112018001995A2 (pt) | moléculas de ácido nucleico artificial | |
| BR112016020688A2 (pt) | Composições úteis no tratamento da deficiência da ornitina transcarbamilase (otc) | |
| BR112018011122A2 (pt) | antígenos, vetores, composições, e métodos de utilização para o vírus da imunodeficiência humana dos mesmos | |
| BR112018073628A2 (pt) | anticorpos antimiostatina e métodos de utilização | |
| CL2018000232A1 (es) | Mezcla de péptidos (divisional solicitud 201601405) | |
| BR112014015016A8 (pt) | Proteína homodimérica de duas cadeias de aminoácidos idênticas, cadeia de aminoácido, molécula de ácido nucléico, composição farmacêutica, célula hospedeira, método de preparação de uma proteína homodimérica, método para preparação de uma vacina, vacina e método de tratamento ou prevenção | |
| EA201600305A1 (ru) | Вариант белка opc2 pcv2 и содержащие его вирусоподобные частицы | |
| BR112012022688A2 (pt) | proteína de fusão, vesícula da membrana externa isolada, polinucleotídeo, composição farmacêutica, vacina, método para tratamento ou prevenção de infecção ou doença por neisseria, uso e método para fabricar uma proteína de fusão | |
| BR112017009177A2 (pt) | vacinas terapêuticas contra hpv16 | |
| BR112016023688A2 (pt) | célula hospedeira, métodos para produzir um bioconjugado, para tratar ou prevenir uma infecção por pseudomonas em um indivíduo e para induzir uma resposta imune contra pseudomonas em um indivíduo, bioconjugado, composição, uso de um bioconjugado ou uma composição, e, sequência de ácido nucleico isolada | |
| BR112018011310A2 (pt) | mutante da proteína l1 do papilomavírus humano tipo 58 | |
| BR112019004770A2 (pt) | anticorpos do vírus antidengue, polipeptídeos contendo regiões fc variantes, e métodos de uso | |
| MX359981B (es) | Virus de sarampión recombinante que expresa polipéptidos del virus de chinkunguña, y sus aplicaciones. | |
| BR112013030150A2 (pt) | proteína l1 hpv33 truncada ou variante da mesma, ácido nucléico isolado, vetor, célula hospedeira, partícula do tipo viral hpv33, composição, composição farmacêutica ou vacina, método para obter uma proteína l1 hpv33 truncada, método para preparar a partícula do tipo viral hpv33, método para preparar uma vacina, método para prevenir a infecção hpv ou uma doença causada pela infecção de hpv e uso da proteína l1 hpv33 truncada ou variante da mesma | |
| CL2012000447A1 (es) | Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica. | |
| BR112017012484A2 (pt) | vírus isolado, cultura celular, gene que codifica uma proteína, proteína, fragmento de dna, vírus de vetor recombinante vivo, pseudo-partícula, vacina, anticorpo ou antissoro, método para a preparação de uma vacina, e, kit de teste diagnóstico. | |
| CO2022003702A2 (es) | Vacunas para vhb y métodos de tratamiento de vhb | |
| BR112015000585A2 (pt) | cepas mutantes de mycoplasma hyopneumoniae | |
| BR112017002809A2 (pt) | métodos para tratar câncer cervical | |
| BR112016015678A2 (pt) | Polipeptídeo contendo fragmentos mutantes de ospa, ácido nucleico, vetor, célula hospedeira, processo para sua produção, composição farmacêutica, e seu uso | |
| AR101468A1 (es) | Vacuna en vector recombinante de adenovirus aviar serotipo 9 | |
| BR112022001075A2 (pt) | Proteína l1 do papilomavírus quimérico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |